Liposomal amphotericin B
Safety and efficacy of liposomal amphotericin B for treatment of complicated visceral leishmaniasis in patients without HIV, North West Ethiopia
... of liposomal amphotericin B, a significant number of critically sick patients were treated with ...and liposomal amphotericin B through its collaborative agreement with the World ...
7
Safety and Efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial
... The effects of VL disease and geographical differences on the pharmacokinetics (PK) of miltefosine remain lar- gely unknown, with most available PK data coming from a relatively healthy European patient group with ...
10
A severe case of visceral leishmaniasis and liposomal amphotericin B treatment failure in an immunosuppressed patient 15 years after exposure
... somal amphotericin B usually leads to rapid clinical improvement and ...somal amphotericin B was adjusted for immunocom- promised patients and his immunosuppressive treatment had been stopped ...
5
Cost analysis of voriconazole versus liposomal amphotericin B for primary therapy of invasive aspergillosis among patients with haematological disorders in Germany and Spain
... versus liposomal amphotericin B as first-line therapies for IA in patients with haematological malignancy and prolonged neutropenia, or those undergoing haematopoietic stem cell transplantation ...
8
Short Course High dose Liposomal Amphotericin B for HIV associated Cryptococcal Meningitis: A phase II Randomized Controlled Trial
... of liposomal amphotericin B were well tolerated, and the safety profile of all liposomal amphotericin B regimens tested compared favourably to data from prior clinical trials ...
30
Introducing single dose liposomal amphotericin B for the treatment of visceral leishmaniasis in rural bangladesh: feasibility and acceptance to patients and health staff.
... Background. For the treatment of visceral leishmaniasis in Bangladesh, single dose liposomal amphotericin B (ambisome) is supposed to be the safest and most effective treatment. Specific needs for ...
7
Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B
... and liposomal amphotericin B treatment groups for ICU and non-ICU ...and liposomal amphotericin B-treated subjects and across the ICU and non-ICU subgroups (Table ...in ...
10
Population Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Children
... Background Liposomal amphotericin B (LAmB) is widely used in the treatment of invasive.. 52.[r] ...
29
Safety and efficacy of liposomal amphotericin B for the empirical therapy of invasive fungal infections in immunocompromised patients
... Abstract: Liposomal amphotericin B is a “true” liposomal formulation of amphotericin B with greatly reduced nephrotoxicity and minimal infusion-related ...manner; ...
8
Single dose liposomal amphotericin B (AmBisome®) for the treatment of Visceral Leishmaniasis in East Africa: study protocol for a randomized controlled trial
... AmBisome ® , a liposomal formulation of Amphotericin B has been shown to be safe and effective against leishma- niasis. In trials in India, an efficacy of 90% was obtained with a single dose of 5 ...
7
Pharmacoeconomic evaluation of voriconazole vs liposomal amphotericin B in empiric treatment of invasive fungal infections in Turkey
... to amphotericin B preparations, data from the US Food and Drug Administration (FDA) sug- gest that voriconazole was inferior to LAmB with respect to overall success rates ...
9
Liposomal Amphotericin-B (AmBisome) for Treatment of Disseminated Fungal Infections in Two Infants of Very Low Birth Weight
... Although blood cultures and cerebro- spinal fluid cultures remained sterile, fungal septicemia was sus- pected and systemic antimycotic treatment with AmBisome was initiated.. As in Case[r] ...
5
Formulation and Evaluation of Long Circulating Liposomal Amphotericin B: A Scinti-kinetic Study using 99mTc in BALB/C Mice
... h was in compliance with the hypothesis which was proposed stating that the long circulating formulation of Amp B will have better residence in the blood. These finding suggests that pegylated liposomes circulated ...
8
Therapeutic and immunomodulatory activities of short course treatment of murine visceral leishmaniasis with KALSOME™10, a new liposomal amphotericin B
... In the absence of a vaccine, chemotherapy is the main- stay to combat the disease. Until the year 2000, pentava- lent antimonials (Sbv) were the frontline treatment for VL. However, with the emergence of antimony ...
12
<p>Acute physiological changes caused by complement activators and amphotericin B-containing liposomes in mice</p>
... and B) and liposomes (Figure 2C and ...if liposomal amphotericin B formulations were administered, it progressed into hypotensive shock after treatment with positive ...
11
Challenges for management of post kala-azar dermal leishmaniasis and future directions
... monotherapy at a dose of 2.5 mg/kg/day for 20 days. It showed 83% of cure rate in persistent PKDL patients who were resistant to SSG therapy. Another advantage of this treatment regimen is its comparatively shorter ...
7
Caspofungin for treatment of invasive aspergillosis in Germany: results of a pre-planned subanalysis of an international registry
... The response rates for caspofungin reported in non-ran- domized studies are in the range 33 to 56% [9,11-13]. In our group of patients the use of caspofungin under real- world conditions in Germany likewise led to high ...
7
Safety Evaluation of Topical Application of Nano-Liposomal Form of Amphotericin B (SinaAmpholeish) on Healthy Volunteers: Phase I Clinical Trial
... The current study was designed to assess the safety of SinaAmpholeish in human healthy volunteers in a double-blind design study completed under the ICH/GCP guidelines (17). Safety and side effects of cosmetic and ...
7
Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh’s National Kala-azar Elimination Programme
... About 100 upazilas (subdistricts) of 26 districts are considered as endemic for VL in Bangladesh. This ac- tivity has been going on since December 2014. Activ- ity area includes secondary public hospital or Upazila ...
13
Empiric treatment against invasive fungal diseases in febrile neutropenic patients: a systematic review and network meta analysis
... of liposomal amphotericin B (L-AmB) was separated as two arms regarding variance between the two ...conventional amphotericin B (AmB) were relatively abundant (three studies that ...
12